tiprankstipranks
Trending News
More News >
Arcutis Biotherapeutics (ARQT)
NASDAQ:ARQT
US Market
Advertisement

Arcutis Biotherapeutics (ARQT) Stock Statistics & Valuation Metrics

Compare
876 Followers

Total Valuation

Arcutis Biotherapeutics has a market cap or net worth of $1.90B. The enterprise value is $1.70B.
Market Cap$1.90B
Enterprise Value$1.70B

Share Statistics

Arcutis Biotherapeutics has 119,905,075 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding119,905,075
Owned by Insiders9.90%
Owned by Institutions55.81%

Financial Efficiency

Arcutis Biotherapeutics’s return on equity (ROE) is -0.89 and return on invested capital (ROIC) is -48.01%.
Return on Equity (ROE)-0.89
Return on Assets (ROA)-0.40
Return on Invested Capital (ROIC)-48.01%
Return on Capital Employed (ROCE)-0.48
Revenue Per Employee574.68K
Profits Per Employee-409.47K
Employee Count342
Asset Turnover0.56
Inventory Turnover1.32

Valuation Ratios

The current PE Ratio of Arcutis Biotherapeutics is ―. Arcutis Biotherapeutics’s PEG ratio is ―.
PE Ratio
PS Ratio
PB Ratio
Price to Fair Value10.70
Price to FCF
Price to Operating Cash Flow-30.31
PEG Ratio

Income Statement

In the last 12 months, Arcutis Biotherapeutics had revenue of 196.54M and earned -140.04M in profits. Earnings per share was -1.16.
Revenue196.54M
Gross Profit177.41M
Operating Income-128.40M
Pretax Income-139.39M
Net Income-140.04M
EBITDA-109.63M
Earnings Per Share (EPS)-1.16

Cash Flow

In the last 12 months, operating cash flow was -65.49M and capital expenditures -5.83M, giving a free cash flow of -71.32M billion.
Operating Cash Flow-65.49M
Free Cash Flow-71.32M
Free Cash Flow per Share-0.59

Dividends & Yields

Arcutis Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.29
52-Week Price Change42.65%
50-Day Moving Average14.92
200-Day Moving Average13.96
Relative Strength Index (RSI)51.69
Average Volume (3m)1.64M

Important Dates

Arcutis Biotherapeutics upcoming earnings date is Nov 5, 2025, After Close (Confirmed).
Last Earnings DateAug 6, 2025
Next Earnings DateNov 5, 2025
Ex-Dividend Date

Financial Position

Arcutis Biotherapeutics as a current ratio of 4.15, with Debt / Equity ratio of 79.27%
Current Ratio4.15
Quick Ratio3.97
Debt to Market Cap0.06
Net Debt to EBITDA-0.36
Interest Coverage Ratio-4.73

Taxes

In the past 12 months, Arcutis Biotherapeutics has paid 647.00K in taxes.
Income Tax647.00K
Effective Tax Rate>-0.01

Enterprise Valuation

Arcutis Biotherapeutics EV to EBITDA ratio is -15.73, with an EV/FCF ratio of -15.35.
EV to Sales8.77
EV to EBITDA-15.73
EV to Free Cash Flow-15.35
EV to Operating Cash Flow-15.37

Balance Sheet

Arcutis Biotherapeutics has $191.13M in cash and marketable securities with $110.16M in debt, giving a net cash position of -$80.97M billion.
Cash & Marketable Securities$191.13M
Total Debt$110.16M
Net Cash-$80.97M
Net Cash Per Share-$0.68
Tangible Book Value Per Share$1.22

Margins

Gross margin is 89.10%, with operating margin of -65.33%, and net profit margin of -71.25%.
Gross Margin89.10%
Operating Margin-65.33%
Pretax Margin-70.92%
Net Profit Margin-71.25%
EBITDA Margin-55.78%
EBIT Margin-57.10%

Analyst Forecast

The average price target for Arcutis Biotherapeutics is $22.16, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$22.16
Price Target Upside43.06% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast99.50%
EPS Growth Forecast65.91%

Scores

Smart Score8
AI Score58
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis